Tumor Necrosis Factor Blocker [EPC]

717522 reported adverse events

Drugs of this class: ETANERCEPT GOLIMUMAB INFLIXIMAB CERTOLIZUMAB PEGOL INFLIXIMAB-AXXQ INFLIXIMAB-DYYB

These side effects are most commonly reported by patients taking drugs of the Tumor Necrosis Factor Blocker [EPC] class:

# Side effect Count
0 DRUG INEFFECTIVE 76273
1 INJECTION SITE PAIN 56163
2 ARTHRALGIA 42841
3 INJECTION SITE ERYTHEMA 41013
4 RHEUMATOID ARTHRITIS 37477
5 PAIN 36872
6 FATIGUE 26943
7 OFF LABEL USE 26710
8 PSORIASIS 26022
9 PAIN IN EXTREMITY 24681
See all common reactions for Tumor Necrosis Factor Blocker [EPC]

Drugs of the Tumor Necrosis Factor Blocker [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 INJECTION SITE RECALL REACTION 481 0.9816
1 HUMAN ANTICHIMERIC ANTIBODY POSITIVE 264 0.9742
2 RED BLOOD CELL SEDIMENTATION RATE ABNORMAL 1236 0.8374
3 ANTI-CYCLIC CITRULLINATED PEPTIDE ANTIBODY POSITIVE 600 0.8253
4 RHEUMATOID FACTOR POSITIVE 1054 0.7937
5 C-REACTIVE PROTEIN ABNORMAL 1892 0.7857
6 INJECTION SITE MACULE 466 0.7397
7 INJECTION SITE WARMTH 10365 0.6482
8 SYNOVITIS 4735 0.6400
9 JOINT DESTRUCTION 607 0.5986
See all enriched reactions for Tumor Necrosis Factor Blocker [EPC]